Adhera Therapeutics, traded on the OTC Markets under the symbol ATRX, is a clinical-stage biotechnology company dedicated to the discovery and development of innovative immunotherapeutic treatments for a range of inflammatory and autoimmune disorders. Leveraging its proprietary Adhera platform, the company focuses on identifying novel targets within key inflammatory pathways and engineering biologic molecules, including monoclonal antibodies, to modulate immune responses. This approach aims to address unmet medical needs in conditions such as asthma, atopic dermatitis and inflammatory bowel disease, where current therapeutic options may be limited or suboptimal.
Founded in 2014 and headquartered in San Diego, California, Adhera Therapeutics has built a pipeline that spans discovery, preclinical evaluation and early-phase clinical trials. The company collaborates with academic research centers and contract research organizations across North America and Europe to advance its lead candidates through development. Recent milestones include the initiation of a Phase I study of the company’s flagship antibody targeting interleukin pathways implicated in chronic inflammatory processes.
In addition to its in-house research and development activities, Adhera maintains strategic partnerships aimed at accelerating the translation of its scientific insights into potential therapies. These alliances provide access to specialized drug manufacturing capabilities, regulatory expertise and clinical trial networks. Adhera’s multidisciplinary team comprises experts in immunology, molecular biology and pharmaceutical development who are committed to advancing the next generation of biologic treatments.
Under the leadership of Chief Executive Officer Dr. Elaine Thompson, a veteran immunologist with over two decades of experience in biotech innovation, and Chief Financial Officer Mark Reynolds, who has overseen finance functions at multiple publicly traded life sciences companies, Adhera Therapeutics continues to pursue its mission of delivering novel therapies to improve patient outcomes. As the company progresses through key development and regulatory milestones, it aims to position itself as a recognized player in the competitive field of immunotherapy for inflammatory diseases.
AI Generated. May Contain Errors.
